ORAL SCAN: Effects Of The Oral JAK Inhibitor Tofacitinib In Combination With Methotrexate On Patient Reported Outcomes In a 24-Month Phase 3 Trial Of Active Rheumatoid Arthritis

被引：0
|
作者：
Strand, V. [1 ]
van der Heijde, D. [2 ]
Zerbini, C. A. F. [3 ]
Connell, C. A. [4 ]
Gruben, D. [4 ]
Riese, R. [4 ]
Wallenstein, G. [4 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Leiden Univ, Med Ctr, Leiden, Netherlands
[3] Ctr Paulista Invest Clin, Sao Paulo, Brazil
[4] Pfizer Inc, Groton, CT 06340 USA
来源：
ARTHRITIS AND RHEUMATISM | 2013年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2334
引用
收藏
页码：S996 / S997
页数：2
相关论文
共 50 条
  • [41] Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study
    van der Heijde, Desiree
    Strand, Vibeke
    Tanaka, Yoshiya
    Keystone, Edward
    Kremer, Joel
    Zerbini, Cristiano A. F.
    Cardiel, Mario H.
    Cohen, Stanley
    Nash, Peter
    Song, Yeong-Wook
    Tegzova, Dana
    Gruben, David
    Wallenstein, Gene
    Connell, Carol A.
    Fleischmann, Roy
    Hall, Stephen
    Nicholls, David
    Rischmueller, Maureen
    Baker, Milton F.
    Bessette, Louis
    Cividino, Alfred A.
    Haraoui, Boulos
    Jones, Henry Niall
    Keystone, Edward
    Khraishi, Majed
    Thorne, J.
    Birbara, Charles Allen
    Baraf, Herbert Stuart Block
    Bathon, Joan Marie
    Brodsky, Alan Lawrence
    Cush, John Joseph
    Dikranian, Ara Hagop
    Diri, Erdal
    Dura, Paul Andrew
    Lohr, Kristine Marie
    Fleischmann, Roy
    Griffin, Robert Michael, Jr.
    Halter, Dale George
    Hargrove, Jody Kay
    Bouda, David William
    Pasya, Suresh Kumar Reddy
    Hill, Geneva Louise
    Jackson, Raymond Edward
    Kafka, Shelly Pearl
    Kaine, Jeffrey Louis
    Katzenstein, Paul L.
    Kempf, Kevin James
    Kolba, Karen Sue
    Kremer, Joel
    Longley, Selden, III
    ARTHRITIS & RHEUMATOLOGY, 2019, 71 (06) : 878 - 891
  • [42] FILGOTINIB (GLPG0634), AN ORAL JAK1 SELECTIVE INHIBITOR IS EFFECTIVE IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: RESULTS FROM A 24-WEEK PHASE 2B DOSE RANGING STUDY
    Westhovens, R.
    Alten, R.
    Pavlova, D.
    Sosa, F. E. Enriquez
    Mazur, M.
    Greenwald, M.
    Van der Aa, A.
    Vanhoutte, F.
    Tasset, C.
    Harrison, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 142 - 142
  • [43] Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, or Adalimumab Versus Placebo in Patients with Rheumatoid Arthritis on Background Methotrexate: A Phase 3 Study.
    van Vollenhoven, R. F.
    Fleischmann, R. M.
    Cohen, S. B.
    Lee, E. B.
    Meijide, G.
    Wagner, S.
    Forejtova, S.
    Zwillich, S. H.
    Gruben, D.
    Koncz, T.
    Wallenstein, G.
    Krishnaswami, S.
    Bradley, J. D.
    Wilkinson, B.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S153 - S153
  • [44] Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
    Fleischmann, Roy
    Mysler, Eduardo
    Hall, Stephen
    Kivitz, Alan J.
    Moots, Robert J.
    Luo, Zhen
    DeMasi, Ryan
    Soma, Koshika
    Zhang, Richard
    Takiya, Liza
    Tatulych, Svitlana
    Mojcik, Christopher
    Krishnaswami, Sriram
    Menon, Sujatha
    Smolen, Josef S.
    LANCET, 2017, 390 (10093): : 457 - 468
  • [45] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: POST-HOC ANALYSES OF EFFICACY AND SAFETY OF MONOTHERAPY VERSUS COMBINATION THERAPY IN A PHASE 3 RHEUMATOID ARTHRITIS POPULATION
    Keystone, E.
    Fleischmann, R.
    van Vollenhoven, R.
    Kremer, J.
    Gruben, D.
    Bradley, J.
    Riese, R.
    Mebus, C.
    Wallenstein, G.
    Zwillich, S. H.
    Benda, B.
    Krishnaswami, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 242 - 242
  • [46] A PHASE 2B, 24-WEEK STUDY OF VX-509 (DECERNOTINIB), AN ORAL SELECTIVE JANUS KINASE 3 INHIBITOR, IN COMBINATION WITH BACKGROUND METHOTREXATE IN RHEUMATOID ARTHRITIS
    van Vollenhoven, R.
    Genovese, M. C.
    Zhang, Y.
    Kinnman, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 118 - 118
  • [47] Improvements in patient reported outcomes over 24 weeks for rituximab with methotrexate in rheumatoid arthritis patients in phase IIb trial (D A N C E R)
    Mease, P
    Szechinski, J
    Greenwald, M
    Leirisalo-Repo, M
    Kivitz, A
    Barile-Fabris, L
    Kalsi, J
    Eames, J
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S138 - S139
  • [48] Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
    Burmester, Gerd R.
    Blanco, Ricardo
    Charles-Schoeman, Christina
    Wollenhaupt, Juergen
    Zerbini, Cristiano
    Benda, Birgitta
    Gruben, David
    Wallenstein, Gene
    Krishnaswami, Sriram
    Zwillich, Samuel H.
    Koncz, Tamas
    Soma, Koshika
    Bradley, John
    Mebus, Charles
    LANCET, 2013, 381 (9865): : 451 - 460
  • [49] EFFECT OF TOFACITINIB ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 3 TRIAL
    Navarro-Compan, V.
    Wei, J. C. C.
    Van den Bosch, F.
    Magrey, M.
    Wang, L.
    Fleishaker, D.
    Cappelleri, J. C.
    Wang, C.
    Wu, J.
    Dina, O.
    Fallon, L.
    Strand, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 704 - 704
  • [50] Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study
    Westhovens, R.
    Alten, Rieke
    Pavlova, Dace
    Enriquez-Sosa, Favio
    Mazur, Minodora
    Greenwald, Maria
    Van der Aa, Annegret
    Vanhoutte, Frederic
    Tasset, Chantal
    Harrison, Pille
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
12345